TY - JOUR
T1 - CPAP increases physical activity in obstructive sleep apnea with cardiovascular disease
AU - Stevens, David
AU - Loffler, Kelly A.
AU - Buman, Matthew P.
AU - Dunstan, David W.
AU - Luo, Yuanming
AU - Lorenzi-Filho, Geraldo
AU - Barbe, Ferran E.
AU - Anderson, Craig S.
AU - McEvoy, R. Doug
AU - The Save Investigators, Save Investigators
N1 - Funding Information:
All authors have seen and approved this manuscript. The SAVE trial was supported by project grants (1006501 [2011-2015] and 1060078 [2014-2016]) from the National Health and Medical Research Council (NHMRC) of Australia and by Respironics Sleep and Respiratory Research Foundation and Philips Respironics. Supplementary trial funding was provided by Fisher & Paykel Healthcare, the Australasian Sleep Trials Network (enabling grant 343020 from the NHMRC), the Spanish Respiratory Society (grant 105-2011), and Fondo de Investigaciones Sanitarias (Grant 13/02053). In-kind donations were provided by Respironics for CPAP equipment and by ResMed for sleep apnea diagnostic devices. All funders had no involvement in the study design, in the collection, analysis, and interpretation of data; in writing of the report; and in the decision to submit the paper for publication. D.W.D. is a Senior Research Fellow of the National Health and Medical Research Council of Australia (NHMRC). F.E.B. received a research grant from ResMed (an Australian company that develops products related to sleep apnea), Philips and the Health Research Fund, Spanish Ministry of Health. C.S.A. holds anNHMRCSenior PrincipalResearch Fellowship and has received fees fromBoehringer Ingelheim and Amgen for participating in advisory panels, from Takeda China and Boehringer Ingelheim for speaking at seminars, and a research grant from Takeda China paid to his institution. R.D.M. held a practitioner fellowship from the NHMRC and reports grants and nonfinancial support from Philips Respironics, nonfinancial support from ResMed, grants from the NHMRC, and grants from Fisher & Paykel, during the conduct of the study; nonfinancial support from Air Liquide; and speaker fees from ResMed. The other authors report no conflicts of interest. Some of these results were presented in abstract form at the 24th Congress of the European Sleep Research Society in Basel, 2018 (P405 in Journal of Sleep Research 27(S1) DOI: 10.1111/jsr.12751.
Funding Information:
All authors have seen and approved this manuscript. The SAVE trial was supported by project grants (1006501 [2011–2015] and 1060078 [2014–2016]) from the National Health and Medical Research Council (NHMRC) of Australia and by Respironics Sleep and Respiratory Research Foundation and Philips Respironics. Supplementary trial funding was provided by Fisher & Paykel Healthcare, the Australasian Sleep Trials Network (enabling grant 343020 from the NHMRC), the Spanish Respiratory Society (grant 105-2011), and Fondo de Investigaciones Sanitarias (Grant 13/02053). In-kind donations were provided by Respironics for CPAP equipment and by ResMed for sleep apnea diagnostic devices. All funders had no involvement in the study design, in the collection, analysis, and interpretation of data; in writing of the report; and in the decision to submit the paper for publication. D.W.D. is a Senior Research Fellow of the National Health and Medical Research Council of Australia (NHMRC). F.E.B. received a research grant from ResMed (an Australian company that develops products related to sleep apnea), Philips and the Health Research Fund, Spanish Ministry of Health. C.S.A. holds an NHMRC Senior Principal Research Fellowship and has received fees from Boehringer Ingelheim and Amgen for participating in advisory panels, from Takeda China and Boehringer Ingelheim for speaking at seminars, and a research grant from Takeda China paid to his institution. R.D.M. held a practitioner fellowship from the NHMRC and reports grants and nonfinancial support from Philips Respironics, nonfinancial support from ResMed, grants from the NHMRC, and grants from Fisher & Paykel, during the conduct of the study; nonfinancial support from Air Liquide; and speaker fees from ResMed. The other authors report no conflicts of interest. Some of these results were presented in abstract form at the 24th Congress of the European Sleep Research Society in Basel, 2018 (P405 in Journal of Sleep Research 27(S1) DOI: 10.1111/jsr.12751.
Publisher Copyright:
© 2021 American Academy of Sleep Medicine. All rights reserved.
PY - 2021/2/1
Y1 - 2021/2/1
N2 - StudyObjectives:Uncertainty exists overwhether continuous positive airway pressure (CPAP) treatment improvesmoderate to vigorous physical activity levels in those with obstructive sleep apnea. We aimed to determine effects of CPAP on moderate to vigorous physical activity among participants with co-occurring cardiovascular disease and obstructive sleep apnea. Methods: The Sleep Apnea cardioVascular Endpoints (SAVE) trial recruited participants with confirmed cardiovascular disease history and obstructive sleep apnea, 45-75 years old. The 2, 687 participants (1, 346 randomized to CPAP plus usual care and 1, 341 to usual care alone) were followed up for a mean of 3.7 years. Self-reported physical activity was recorded at baseline, 6, 24, and 48 months using the Godin-Shepard Leisure Time Exercise Questionnaire (LTEQ). We also determined effects on any limitation of physical activity reported on the physical functioning subscale of the 36-item short form questionnaire (SF-36) and proportions of participants reaching guideline recommended physical activity levels. Results: Among 2, 601 participants with available data, those in the CPAP group reported significantly more physical activity compared to the usual care group, with approximately 20% higher reported moderate activities on the LTEQ during follow-up (adjusted mean 95% confidence interval) scores: 8.7, 7.5-9.9 vs 7.3, 6.1-8.5; P = .003). Those in the CPAP group also reported less limitation in physical activity (adjusted between-group difference in SF-36 physical functioning subscale score 1.66, 95%confidence interval 0.87-2.45; P < 0.001), andmore reported sufficient levels of physical activity tomeet recommendations. Conclusions: CPAP has positive effects on improving physical activity levels, consistent with long-term health benefits.
AB - StudyObjectives:Uncertainty exists overwhether continuous positive airway pressure (CPAP) treatment improvesmoderate to vigorous physical activity levels in those with obstructive sleep apnea. We aimed to determine effects of CPAP on moderate to vigorous physical activity among participants with co-occurring cardiovascular disease and obstructive sleep apnea. Methods: The Sleep Apnea cardioVascular Endpoints (SAVE) trial recruited participants with confirmed cardiovascular disease history and obstructive sleep apnea, 45-75 years old. The 2, 687 participants (1, 346 randomized to CPAP plus usual care and 1, 341 to usual care alone) were followed up for a mean of 3.7 years. Self-reported physical activity was recorded at baseline, 6, 24, and 48 months using the Godin-Shepard Leisure Time Exercise Questionnaire (LTEQ). We also determined effects on any limitation of physical activity reported on the physical functioning subscale of the 36-item short form questionnaire (SF-36) and proportions of participants reaching guideline recommended physical activity levels. Results: Among 2, 601 participants with available data, those in the CPAP group reported significantly more physical activity compared to the usual care group, with approximately 20% higher reported moderate activities on the LTEQ during follow-up (adjusted mean 95% confidence interval) scores: 8.7, 7.5-9.9 vs 7.3, 6.1-8.5; P = .003). Those in the CPAP group also reported less limitation in physical activity (adjusted between-group difference in SF-36 physical functioning subscale score 1.66, 95%confidence interval 0.87-2.45; P < 0.001), andmore reported sufficient levels of physical activity tomeet recommendations. Conclusions: CPAP has positive effects on improving physical activity levels, consistent with long-term health benefits.
KW - Continuous positive airway pressure
KW - Obstructive sleep apnea
KW - Physical activity
UR - http://www.scopus.com/inward/record.url?scp=85101387907&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101387907&partnerID=8YFLogxK
U2 - 10.5664/JCSM.8792
DO - 10.5664/JCSM.8792
M3 - Article
C2 - 32951632
AN - SCOPUS:85101387907
SN - 1550-9389
VL - 17
SP - 141
EP - 148
JO - Journal of Clinical Sleep Medicine
JF - Journal of Clinical Sleep Medicine
IS - 2
ER -